17:34 , Jun 2, 2017 |  BioCentury  |  Emerging Company Profile

Prolonging thrombin production

ApcinteX Ltd. is betting that inhibiting an endogenous brake on thrombin production will generate a therapy for hemophilia A and B that can be used by patients who have developed neutralizing antibodies to factor replacement...
02:42 , Feb 11, 2017 |  BioCentury  |  Finance

Dynamic duo

The asset-centric model of venture investing often sees a VC working with a stable of serial entrepreneurs who are deployed to new companies when the ones they have founded or helmed are sold. But few...
13:36 , Feb 9, 2017 |  BC Extra  |  Financial News

SuperX raises $11M series A round

Anticoagulation play SuperX Ltd. (Cambridge, U.K.) raised $11 million in a series A round led by Medicxi . Johnson & Johnson Innovation-JJDC Inc. also participated. The newco is developing preclinical antibodies against an undisclosed target...
17:34 , Feb 3, 2017 |  BC Week In Review  |  Financial News

ApcinteX completes venture financing

Hemophilia play ApcinteX Ltd. (Cambridge, U.K.) raised £14 million ($17.5 million) in a series A round co-led by Touchstone Innovations and Medicxi on Feb. 2. ApcinteX Ltd. , Cambridge, U.K. ...